Abstract:
Objective This work aims to observe the short-term efficacy of Abraxane in treating patients with metastatic breast cancer.
Methods A total of 75 patients with advanced and metastatic breast cancer were randomized into two groups. Group One (test group) comprised 37 patients who were treated with Abraxane monotherapy. Group Two (control group) comprised 38 patients who were treated with conventional injection of single-agent paclitaxel medication. The two groups were observed for short-term efficacy and adverse events.
Results In Group One, complete remission (CR) was found in 1 patient, partial remission (PR) in 15, stable disease (SD) in 14, and progression of disease (PD) in 7. In Group Two, CR was not observed, PR in 9, SD in 19, and PD in 10 patients. The total remission rates in Groups One and Two were 43.24% and 23.68%, respectively. The most commonly observed adverse events in the two groups were myelo-supression and neurotoxicity.
Conclusion Abraxane treatment of metastatic breast cancer has a favorable therapeutic efficacy, and the adverse reactions are tolerable.